- Oncolytics Biotech (NASDAQ:ONCY) has entered into a Master Clinical Supply Agreement (Agreement) with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq) for use in the company’s clinical development program.
- The supply agreement enables to further investigate pelareorep’s impact on cancer treatments in combination with atezolizumab.
- Under this five-year Master Clinical Supply Agreement, Roche will supply atezolizumab for the proposed clinical trial with both parties having access to the clinical data.